Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

98.89 +1.27 (+1.30%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts ↗
The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
Via The Motley Fool
News headline image
Is It Time to Buy September's Worst-Performing Dow Jones Stocks? ↗
They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices. 
Via The Motley Fool
Topics Stocks
News headline image
3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Check out these three bargain stock that missed out on the rally to market highs, but have reasons for optimism going forward. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses ↗
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization... 
Via Benzinga
News headline image
Demystifying Merck & Co: Insights From 8 Analyst Reviews ↗
 
Via Benzinga
News headline image
Exploring The Competitive Space: Merck &amp; Co Versus Industry Peers In Pharmaceuticals ↗
 
Via Benzinga
News headline image
Could Summit Therapeutics Become the Next Merck? ↗
Recent developments are forcing comparisons between these two drugmakers. 
Via The Motley Fool
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
News headline image
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Is Merck Stock a Buy? ↗
There is mounting pressure on the company's most prized franchise. 
Via The Motley Fool
News headline image
This Is What Whales Are Betting On Merck & Co ↗
 
Via Benzinga
News headline image
Merck & Co Unusual Options Activity For September 23 ↗
 
Via Benzinga
News headline image
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
News headline image
The Covid Era Tech Promises To Reinvent Cancer Treatment ↗
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
Via Benzinga
News headline image
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct
News headline image
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
From Merck & Co., Inc.
Via Business Wire
News headline image
2 High-Potential Growth Stocks You Shouldn't Overlook ↗
These two growth stocks have plenty of room to run. 
Via The Motley Fool
News headline image
Evaxion Biotech Partners With Merck To Expand Vaccine Development ↗
Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates. The deal includes $3.2 million upfront and potential earnings up to $592... 
Via Benzinga
News headline image
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
From Merck & Co., Inc.
Via Business Wire
News headline image
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers. 
Via Benzinga
News headline image
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years ↗
Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and... 
Via Benzinga
News headline image
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study ↗
Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained... 
Via Benzinga
News headline image
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
From Merck & Co., Inc.
Via Business Wire
News headline image
Pfizer Advances On Its Cancer Journey ↗
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
Via Benzinga
News headline image
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.